银屑病关节炎的诊治现状与挑战
戴生明 . 银屑病关节炎的诊治现状与挑战[J]. 内科理论与实践, 2022 , 17(03) : 186 -189 . DOI: 10.16138/j.1673-6087.2022.03.002
[1] | FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis[J]. Nat Rev Dis Primers, 2021, 7(1): 59. |
[2] | Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome[J]. Ann Rheum Dis, 2005, 64 Suppl 2:ii14-ii17. |
[3] | van der Heijde D, Gladman DD, Kavanaugh A, et al. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research[J]. Arthritis Res Ther, 2020, 22(1): 18. |
[4] | McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study[J]. Rheumatology (Oxford), 2003, 42(6): 778-783. |
[5] | Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study[J]. Rheumatology(Oxford), 2019, 58(1): 144-148. |
[6] | Favarato MH, Mease P, Gonçalves CR, et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis[J]. Clin Exp Rheumatol, 2014, 32(2): 182-187. |
[7] | Szentpetery A, Healy GM, Brady D, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity[J]. Arthritis Rheumatol, 70(3): 396-407. |
[8] | Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone[J]. Rheumatology, 2012, 51(3):571-576. |
[9] | Chen Z, Xu Y, Chen M, et al. Gout augments the risk of cardiovascular disease in patients with psoriasis[J]. Front Immunol, 2021, 12: 703119. |
[10] | 丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查[J]. 中国皮肤性病学杂志, 2010, 24(7): 598-601. |
[11] | Reich K, Krüger K, Mössner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis[J]. Br J Dermatol, 2009, 160(5): 1040-1047. |
[12] | Guillen Astete CA, Gaite Gonzalez I, Zurita Prada PA, et al. Delay and diagnostic pathway of patients with psoriatic arthritis in Spain[J]. Reumatol Clin (Engl Ed), 2020, 17(9): 525-529. |
[13] | Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis[J]. J Rheumatol, 2021, 48(9): 1410-1416. |
[14] | Cui R, Chen M, Li X, et al. Assessment of four screening tools and retrieval of key questions to detect undiagnosed psoriatic arthritis in Chinese patients with psoriasis[J]. J Dermatol, 2022, 49(6): 615-623. |
[15] | Tinazzi I, Adami S, Zanolin EM, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis[J]. Rheumatology, 2012, 51(11): 2058-2063. |
[16] | Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire[J]. Clin Exp Rheumatol, 2009, 27(3): 469-474. |
[17] | Lindqvist UR, Alenius GM, Husmark T, et al. The Swedish early psoriatic arthritis register- 2-year followup[J]. J Rheumatol, 2008, 35(4): 668-673. |
[18] | Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience[J]. Rheumatology, 2003, 42(12): 1460-1468. |
[19] | Kane D, Pathare S. Early psoriatic arthritis[J]. Rheum Dis Clin North Am, 2005, 31(4): 641-657. |
[20] | Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis[J]. Ann Rheum Dis, 2015, 74(6): 1045-1050. |
[21] | Weisman MH, Witter JP, Reveille JD. The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10[J]. Ann Rheum Di, 2013, 72(3): 369-373. |
[22] | Dai SM, Han XH, Zhao DB, et al. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China[J]. J Rheumatol, 2003, 30(10): 2245-2251. |
[23] | Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China[J]. Rheumatol Int, 2009, 29(5): 481-490. |
[24] | Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis[J]. Rheumatology (Oxford), 2012, 51(8):1368-1377. |
[25] | Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis[J]. Ann Rheum Dis, 2016, 75(3): 490-498. |
[26] | Acosta Felquer ML, Coates LC, Soriano ER, et al. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review[J]. J Rheumatol, 2014, 41(11): 2277-2285. |
[27] | Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial[J]. Arthritis Rheum, 2004, 50(6): 1939-1950. |
[28] | Zardin-Moraes M, da Silva ALFA, Saldanha C, et al. Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials[J]. J Rheumatol, 2020, 47(6): 839-846. |
[29] | Chen M, Zhang H, Chen Z, et al. Perceptions of rheumatologists on diagnosis of psoriatic arthritis in China[J]. Front Immunol, 2021, 12:733708. |
/
〈 |
|
〉 |